


**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims**


Claims 1-7 (cancelled)

Claim 8 (original): A compound of the formula



or a pharmaceutically acceptable salt thereof.

Claim 9 (original): A compound of the formula




or a pharmaceutically acceptable salt thereof.

Claim 10 (cancelled)


Claim 11 (cancelled)

Claim 12 (original): A compound of the formula



or a pharmaceutically acceptable salt thereof.


Claim 13 (original): A compound of the formula



or a pharmaceutically acceptable salt thereof.

Claims 14-18 (cancelled)

Claim 19 (currently amended): A method for the treatment or prophylaxis of an HIV-infection in a host comprising administering to said host an effective anti-HIV treatment amount of a compound of claim 1, formula (I):



or its a pharmaceutically acceptable salt thereof, wherein

R<sup>1</sup> is hydrogen; acyl; -C(=O)H; -C(=W)H; -C(=O)R<sup>2</sup>; -C(=W)R<sup>2</sup>; -C(=O)OH; -C(=W)OH; -C(=O)OR<sup>2</sup>; -C(=W)OR<sup>2</sup>; -C(=O)SH; -C(=W)SH; -C(=O)SR<sup>2</sup>; -C(=W)SR<sup>2</sup>; -C(=O)NH<sub>2</sub>; -C(=W)NH<sub>2</sub>; -C(=O)NHR<sup>2</sup>; -C(=W)NHR<sup>2</sup>; -C(=O)NR<sup>2</sup>R<sup>3</sup>; -C(=W)NR<sup>2</sup>R<sup>3</sup>; -C(=W)NH-(CH<sub>2</sub>)<sub>p</sub>-(amino acid); or -(CH<sub>2</sub>)<sub>p</sub>-(amino acid);

R<sup>4'</sup>, R<sup>5'</sup>, R<sup>6'</sup>, R<sup>7'</sup>, R<sup>2''</sup>, R<sup>3''</sup>, R<sup>4''</sup>, R<sup>5''</sup> and R<sup>6''</sup> are each independently H; halo; -NO<sub>2</sub>; -CN; -OH; -OR<sup>2</sup>; -SH; -SR<sup>2</sup>; -NH<sub>2</sub>; -NHR<sup>2</sup>; -NR<sup>2</sup>R<sup>3</sup>; -NHSO<sub>2</sub>-C<sub>1-3</sub>alkyl; -NR<sup>2</sup>SO<sub>2</sub>-C<sub>1-3</sub>alkyl; -NHCO-C<sub>1-3</sub>alkyl; -NR<sup>2</sup>CO-C<sub>1-3</sub>alkyl; optionally substituted or unsubstituted branched or unbranched alkyl, alkenyl or alkynyl; CH<sub>3</sub>; CF<sub>3</sub>; vinyl bromide; -CR<sup>2</sup>R<sup>2</sup>-S(O)<sub>n</sub>-R<sup>3</sup>; -CR<sup>2</sup>R<sup>2</sup>NH<sub>2</sub>; -CR<sup>2</sup>R<sup>2</sup>NHR<sup>2</sup>; -CR<sup>2</sup>R<sup>2</sup>NR<sup>2</sup>R<sup>3</sup>; -CR<sup>2</sup>R<sup>2</sup>-C(=O)R<sup>2</sup>; alkacyl; optionally substituted or unsubstituted acyl; -C(=O)H; -C(=W)H; -C(=O)R<sup>2</sup>; -C(=W)R<sup>2</sup>; -C(=O)OH; -C(=W)OH; -C(=O)OR<sup>2</sup>; -C(=W)OR<sup>2</sup>; -C(=O)SH; -C(=W)SH; -C(=O)SR<sup>2</sup>; -C(=W)SR<sup>2</sup>; -C(=O)NH<sub>2</sub>; -C(=W)NH<sub>2</sub>; -C(=O)NHR<sup>2</sup>; -C(=W)NHR<sup>2</sup>; -C(=O)NR<sup>2</sup>R<sup>3</sup>; -C(=W)NR<sup>2</sup>R<sup>3</sup>; -C(=W)NH(CH<sub>2</sub>)<sub>p</sub>-(amino acid); an amino acid; or -(CH<sub>2</sub>)<sub>p</sub>(amino acid);

wherein if R<sup>5'</sup> is hydrogen, F, Cl, Br, -NO<sub>2</sub>, -CN, -OR<sup>2</sup>, -NR<sup>2</sup>R<sup>2</sup>, -NHSO<sub>2</sub>-C<sub>1-3</sub>alkyl; or -NHCO-C<sub>1-3</sub>alkyl, then at least one of R<sup>4'</sup>, R<sup>6'</sup> and R<sup>7'</sup> is not hydrogen; or alternatively, wherein at least two of R<sup>4'</sup>, R<sup>5'</sup>, R<sup>6'</sup>, R<sup>7'</sup> are not hydrogen;

Z is optionally substituted or unsubstituted acyl, -C(=O)NH<sub>2</sub>; -C(=W)-NH<sub>2</sub>; -C(=O)NHR<sup>2</sup>; -C(=W)NHR<sup>2</sup>; -C(=O)NR<sup>2</sup>R<sup>3</sup>; -C(=W)NR<sup>2</sup>R<sup>3</sup>; -C(=W)NH(CH<sub>2</sub>)<sub>p</sub>-(amino acid); an amino acid; -(CH<sub>2</sub>)<sub>p</sub>-(amino acid); -C(=O)R<sup>3</sup>; -C(=O)H; -C(=W)H; -C(=O)R<sup>2</sup>; -C(=W)R<sup>2</sup>; -C(=O)OR<sup>3</sup>; -C(=O)OH; -C(=W)OH; -C(=O)OR<sup>2</sup>; -C(=W)OR<sup>2</sup>; -C(=O)-SH; -C(=W)SH; -C(=O)SR<sup>2</sup>; -C(=W)SR<sup>2</sup>; optionally substituted or unsubstituted branched or unbranched alkyl, alkenyl or alkynyl; CH<sub>3</sub>; CF<sub>3</sub>; vinyl

bromide;  $-\text{CR}^2\text{R}^2-\text{S}(\text{O})_n-\text{R}^3$ ;  $-\text{CR}^2\text{R}^2\text{NH}_2$ ;  $-\text{CR}^2\text{R}^2\text{NHR}^2$ ;  $-\text{CR}^2\text{R}^2\text{NR}^2\text{R}^3$ ;  $-\text{CR}^2\text{R}^2-\text{C}(=\text{O})\text{R}^2$ ;  $-\text{CN}$ ; or halo;

Y is O; S; or  $\text{S}(\text{O})_n$ ;

each W is independently O; S;  $-\text{NH}_2$ ;  $-\text{NHR}^2$ ;  $-\text{NR}^2\text{R}^2$ ;  $-\text{N-CN}$ ;  $-\text{N-NH}_2$ ;  $-\text{N-NHR}^2$ ;  $-\text{N-NR}^2\text{R}^3$ ;  $-\text{N-OH}$ ; or  $-\text{N-OR}^2$ ;

each  $\text{R}^2$  is independently hydrogen; an optionally substituted or unsubstituted branched or unbranched lower alkyl, alkenyl or alkynyl;  $\text{CH}_3$ ;  $\text{CF}_3$ ; or vinyl bromide;

each  $\text{R}^3$  is independently hydrogen; optionally substituted or unsubstituted branched or unbranched alkyl, alkenyl or alkynyl;  $\text{CH}_3$ ;  $\text{CF}_3$ ; vinyl bromide;  $-\text{CR}^2\text{R}^2-\text{S}(\text{O})_n-\text{R}^2$ ;  $-\text{CR}^2\text{R}^2\text{NH}_2$ ;  $-\text{CR}^2\text{R}^2\text{NHR}^2$ ;  $-\text{CR}^2\text{R}^2\text{NR}^2\text{R}^2$ ;  $-\text{CR}^2\text{R}^2-\text{C}(=\text{O})\text{R}^2$ ; optionally substituted or unsubstituted aryl; optionally substituted or unsubstituted heterocycle; optionally substituted or unsubstituted alkylaryl; optionally substituted or unsubstituted alkylheterocycle; optionally substituted or unsubstituted aralkyl; or optionally substituted or unsubstituted heterocycle-alkyl;


each n is independently 0, 1 or 2;

each p is independently 0, 1, 2, 3, 4 or 5; and

wherein the optionally substituted branched or unbranched alkyl, alkenyl, alkynyl, lower alkyl, lower alkenyl; lower alkynyl; acyl; aryl; heterocycle; alkaryl; alkheterocycle; arylalkyl; or alkylheterocycle optionally is substituted with one or more of halogen;  $-\text{OH}$ ;  $-\text{OR}^2$ ;  $-\text{SH}$ ;  $-\text{SR}^2$ ; oxime; hydrazine;  $-\text{C}(=\text{O})\text{H}$ ;  $-\text{C}(=\text{W})\text{H}$ ;  $-\text{C}(=\text{O})\text{R}^2$ ;  $-\text{C}(=\text{W})\text{R}^2$ ;  $-\text{C}(=\text{O})\text{OH}$ ;  $-\text{C}(=\text{W})\text{OH}$ ;  $-\text{C}(=\text{O})\text{OR}^2$ ;  $-\text{C}(=\text{W})\text{OR}^2$ ;  $-\text{C}(=\text{O})\text{SH}$ ;  $-\text{C}(=\text{W})\text{SH}$ ;  $-\text{C}(=\text{O})\text{SR}^2$ ;  $-\text{C}(=\text{W})\text{SR}^2$ ;  $-\text{C}(=\text{O})\text{NH}_2$ ;  $-\text{C}(=\text{W})\text{NH}_2$ ;  $-\text{C}(=\text{O})-\text{NHR}^2$ ;  $-\text{C}(=\text{W})\text{NHR}^2$ ;  $-\text{C}(=\text{O})\text{NR}^2\text{R}^3$ ;  $-\text{C}(=\text{W})-\text{NR}^2\text{R}^3$ ;  $-\text{NH}_2$ ;  $-\text{NHR}^2$ ;  $-\text{NR}^2\text{R}^3$ ;  $-\text{NHSO}_2-\text{C}_{1-3}\text{alkyl}$ ;  $-\text{NR}^2\text{SO}_2-\text{C}_{1-3}\text{alkyl}$ ;  $-\text{NHCO}-\text{C}_{1-3}\text{alkyl}$ ;  $-\text{NR}^2\text{CO}-\text{C}_{1-3}\text{alkyl}$ ;  $-\text{S}(\text{O})_n-\text{R}^3$ ;  $\text{C}_{1-3}$  alkoxy;  $\text{C}_{1-3}$ thioether; or an amino acid residue;

optionally in a pharmaceutically acceptable carrier or diluent.

Claim 20 (currently amended): A method for the treatment or prophylaxis of an HIV-infection in a host comprising administering to said host an effective anti-HIV treatment amount of a compound of ~~claim 1~~, formula (I):



or its a pharmaceutically acceptable salt thereof, wherein

R¹ is hydrogen; acyl; -C(=O)H; -C(=W)H; -C(=O)R²; -C(=W)R²; -C(=O)OH; -C(=W)OH; -C(=O)OR²; -C(=W)OR²; -C(=O)SH; -C(=W)SH; -C(=O)SR²; -C(=W)SR²; -C(=O)NH₂; -C(=W)NH₂; -C(=O)NHR²; -C(=W)NHR²; -C(=O)NR²R³; -C(=W)NR²R³; -C(=W)NH-(CH₂)<sub>n</sub>-(amino acid); or -(CH₂)<sub>n</sub>-(amino acid);

R⁴, R⁵, R⁶, R⁷, R², R³, R⁴, R⁵ and R⁶ are each independently H; halo; -NO₂; -CN; -OH; -OR²; -SH; -SR²; -NH₂; -NHR²; -NR²R³; -NHSO₂-C₁-₃alkyl; -NR²SO₂-C₁-₃alkyl; -NHCO-C₁-₃alkyl; -NR²CO-C₁-₃alkyl; optionally substituted or unsubstituted branched or unbranched alkyl, alkenyl or alkynyl; CH₃; CF₃; vinyl bromide; -CR²R²-S(O)<sub>n</sub>-R³; -CR²R²NH₂; -CR²R²NHR²; -CR²R²NR²R³; -CR²R²-C(=O)R²; alkacyl; optionally substituted or unsubstituted acyl; -C(=O)H; -C(=W)H; -C(=O)R²; -C(=W)R²; -C(=O)OH; -C(=W)OH; -C(=O)OR²; -C(=W)OR²; -C(=O)SH; -C(=W)SH; -C(=O)SR²; -C(=W)SR²; -C(=O)NH₂; -C(=W)NH₂; -C(=O)NHR²; -C(=W)NHR²; -C(=O)NR²R³; -C(=W)NR²R³; -C(=W)NH-(CH₂)<sub>n</sub>-(amino acid); an amino acid; or -(CH₂)<sub>n</sub>(amino acid);

wherein if R⁵ is hydrogen, F, Cl, Br, -NO₂, -CN, -OR², -NR²R², -NHSO₂-C₁-₃alkyl; or -NHCO-C₁-₃alkyl, then at least one of R⁴, R⁶ and R⁷ is not hydrogen; or alternatively, wherein at least two of R⁴, R⁵, R⁶, R⁷ are not hydrogen;

Z is optionally substituted or unsubstituted acyl, -C(=O)NH₂; -C(=W)-NH₂; -C(=O)NHR²; -C(=W)NHR²; -C(=O)NR²R³; -C(=W)NR²R³; -C(=W)NH-(CH₂)<sub>n</sub>-(amino acid); an amino acid; -(CH₂)<sub>n</sub>-(amino acid); -C(=O)R³; -C(=O)H; -C(=W)H; -C(=O)R²; -C(=W)R²; -C(=O)OR³; -C(=O)OH; -C(=W)OH; -C(=O)OR²; -C(=W)OR²; -C(=O)-SH; -C(=W)SH; -C(=O)SR²; -C(=W)SR²; optionally substituted or unsubstituted branched or unbranched alkyl, alkenyl or alkynyl; CH₃; CF₃; vinyl

bromide;  $-\text{CR}^2\text{R}^2-\text{S}(\text{O})_n-\text{R}^3$ ;  $-\text{CR}^2\text{R}^2\text{NH}_2$ ;  $-\text{CR}^2\text{R}^2\text{NHR}^2$ ;  $-\text{CR}^2\text{R}^2\text{NR}^2\text{R}^3$ ;  $-\text{CR}^2\text{R}^2-\text{C}(=\text{O})\text{R}^2$ ;  $-\text{CN}$ ; or halo;

Y is O; S; or  $\text{S}(\text{O})_n$ ;

each W is independently O; S;  $-\text{NH}_2$ ;  $-\text{NHR}^2$ ;  $-\text{NR}^2\text{R}^2$ ;  $-\text{N-CN}$ ;  $-\text{N-NH}_2$ ;  $-\text{N-NHR}^2$ ;  $-\text{N-NR}^2\text{R}^3$ ;  $-\text{N-OH}$ ; or  $-\text{N-OR}^2$ ;

each  $\text{R}^2$  is independently hydrogen; an optionally substituted or unsubstituted branched or unbranched lower alkyl, alkenyl or alkynyl;  $\text{CH}_3$ ;  $\text{CF}_3$ ; or vinyl bromide;

each  $\text{R}^3$  is independently hydrogen; optionally substituted or unsubstituted branched or unbranched alkyl, alkenyl or alkynyl;  $\text{CH}_3$ ;  $\text{CF}_3$ ; vinyl bromide;  $-\text{CR}^2\text{R}^2-\text{S}(\text{O})_n-\text{R}^2$ ;  $-\text{CR}^2\text{R}^2\text{NH}_2$ ;  $-\text{CR}^2\text{R}^2\text{NHR}^2$ ;  $-\text{CR}^2\text{R}^2\text{NR}^2\text{R}^2$ ;  $-\text{CR}^2\text{R}^2-\text{C}(=\text{O})\text{R}^2$ ; optionally substituted or unsubstituted aryl; optionally substituted or unsubstituted heterocycle; optionally substituted or unsubstituted alkylaryl; optionally substituted or unsubstituted alkylheterocycle; optionally substituted or unsubstituted aralkyl; or optionally substituted or unsubstituted heterocycle-alkyl;

each n is independently 0, 1 or 2;

each p is independently 0, 1, 2, 3, 4 or 5; and


wherein the optionally substituted branched or unbranched alkyl, alkenyl, alkynyl, lower alkyl, lower alkenyl; lower alkynyl; acyl; aryl; heterocycle; alkaryl; alkheterocycle; arylalkyl; or alkylheterocycle optionally is substituted with one or more of halogen;  $-\text{OH}$ ;  $-\text{OR}^2$ ;  $-\text{SH}$ ;  $-\text{SR}^2$ ; oxime; hydrazine;  $-\text{C}(=\text{O})\text{H}$ ;  $-\text{C}(=\text{W})\text{H}$ ;  $-\text{C}(=\text{O})\text{R}^2$ ;  $-\text{C}(=\text{W})\text{R}^2$ ;  $-\text{C}(=\text{O})\text{OH}$ ;  $-\text{C}(=\text{W})\text{OH}$ ;  $-\text{C}(=\text{O})\text{OR}^2$ ;  $-\text{C}(=\text{W})\text{OR}^2$ ;  $-\text{C}(=\text{O})\text{SH}$ ;  $-\text{C}(=\text{W})\text{SH}$ ;  $-\text{C}(=\text{O})\text{SR}^2$ ;  $-\text{C}(=\text{W})\text{SR}^2$ ;  $-\text{C}(=\text{O})\text{NH}_2$ ;  $-\text{C}(=\text{W})\text{NH}_2$ ;  $-\text{C}(=\text{O})-\text{NHR}^2$ ;  $-\text{C}(=\text{W})\text{NHR}^2$ ;  $-\text{C}(=\text{O})\text{NR}^2\text{R}^3$ ;  $-\text{C}(=\text{W})-\text{NR}^2\text{R}^3$ ;  $-\text{NH}_2$ ;  $-\text{NHR}^2$ ;  $-\text{NR}^2\text{R}^3$ ;  $-\text{NHSO}_2-\text{C}_{1-3}\text{alkyl}$ ;  $-\text{NR}^2\text{SO}_2-\text{C}_{1-3}\text{alkyl}$ ;  $-\text{NHCO}-\text{C}_{1-3}\text{alkyl}$ ;  $-\text{NR}^2\text{CO}-\text{C}_{1-3}\text{alkyl}$ ;  $-\text{S}(\text{O})_n-\text{R}^3$ ;  $\text{C}_{1-3}$  alkoxy;  $\text{C}_{1-3}$ thioether; or an amino acid residue;

in combination and/or alternation with one or more other anti-HIV agent, optionally in a pharmaceutically acceptable carrier or diluent.

Claim 21 (original): The method of claim 20, wherein the other anti-HIV agent is a reverse transcriptase inhibitor.

Claim 22 (original): The method of claim 21, wherein the reverse transcriptase inhibitor induces a mutation lysine 103  $\rightarrow$  asparagine and/or tyrosine 181  $\rightarrow$  cysteine in HIV reverse transcriptase.

Claim 23 (currently amended): A method for the treatment or prophylaxis of an HIV-infection in a host, wherein the HIV has a mutation at lysine 103 → asparagine and/or tyrosine 181 → cysteine in HIV reverse transcriptase, comprising administering to said host an effective anti-HIV treatment amount of a compound of ~~claim 1~~, formula (I):



or its a pharmaceutically acceptable salt thereof, wherein

R<sup>1</sup> is hydrogen; acyl; -C(=O)H; -C(=W)H; -C(=O)R<sup>2</sup>; -C(=W)R<sup>2</sup>; -C(=O)OH; -C(=W)OH; -C(=O)OR<sup>2</sup>; -C(=W)OR<sup>2</sup>; -C(=O)SH; -C(=W)SH; -C(=O)SR<sup>2</sup>; -C(=W)SR<sup>2</sup>; -C(=O)NH<sub>2</sub>; -C(=W)NH<sub>2</sub>; -C(=O)NHR<sup>2</sup>; -C(=W)NHR<sup>2</sup>; -C(=O)NR<sup>2</sup>R<sup>3</sup>; -C(=W)NR<sup>2</sup>R<sup>3</sup>; -C(=W)NH-(CH<sub>2</sub>)<sub>n</sub>-(amino acid); or -(CH<sub>2</sub>)<sub>n</sub>-(amino acid);

R<sup>4'</sup>, R<sup>5'</sup>, R<sup>6'</sup>, R<sup>7'</sup>, R<sup>2''</sup>, R<sup>3''</sup>, R<sup>4''</sup>, R<sup>5''</sup> and R<sup>6''</sup> are each independently H; halo; -NO<sub>2</sub>; -CN; -OH; -OR<sup>2</sup>; -SH; -SR<sup>2</sup>; -NH<sub>2</sub>; -NHR<sup>2</sup>; -NR<sup>2</sup>R<sup>3</sup>; -NHSO<sub>2</sub>-C<sub>1-3</sub>alkyl; -NR<sup>2</sup>SO<sub>2</sub>-C<sub>1-3</sub>alkyl; -NHCO-C<sub>1-3</sub>alkyl; -NR<sup>2</sup>CO-C<sub>1-3</sub>alkyl; optionally substituted or unsubstituted branched or unbranched alkyl, alkenyl or alkynyl; CH<sub>3</sub>; CF<sub>3</sub>; vinyl bromide; -CR<sup>2</sup>R<sup>2</sup>-S(O)<sub>n</sub>-R<sup>3</sup>; -CR<sup>2</sup>R<sup>2</sup>NH<sub>2</sub>; -CR<sup>2</sup>R<sup>2</sup>NHR<sup>2</sup>; -CR<sup>2</sup>R<sup>2</sup>NR<sup>2</sup>R<sup>3</sup>; -CR<sup>2</sup>R<sup>2</sup>-C(=O)R<sup>2</sup>; alkacyl; optionally substituted or unsubstituted acyl; -C(=O)H; -C(=W)H; -C(=O)R<sup>2</sup>; -C(=W)R<sup>2</sup>; -C(=O)OH; -C(=W)OH; -C(=O)OR<sup>2</sup>; -C(=W)OR<sup>2</sup>; -C(=O)-SH; -C(=W)SH; -C(=O)SR<sup>2</sup>; -C(=W)SR<sup>2</sup>; -C(=O)NH<sub>2</sub>; -C(=W)NH<sub>2</sub>; -C(=O)NHR<sup>2</sup>; -C(=W)NHR<sup>2</sup>; -C(=O)NR<sup>2</sup>R<sup>3</sup>; -C(=W)NR<sup>2</sup>R<sup>3</sup>; -C(=W)NH(CH<sub>2</sub>)<sub>n</sub>-(amino acid); an amino acid; or -(CH<sub>2</sub>)<sub>n</sub>(amino acid);

wherein if R<sup>5'</sup> is hydrogen, F, Cl, Br, -NO<sub>2</sub>, -CN, -OR<sup>2</sup>, -NR<sup>2</sup>R<sup>2</sup>, -NHSO<sub>2</sub>-C<sub>1-3</sub>alkyl; or -NHCO-C<sub>1-3</sub>alkyl, then at least one of R<sup>4'</sup>, R<sup>6'</sup> and R<sup>7'</sup> is not hydrogen; or alternatively, wherein at least two of R<sup>4'</sup>, R<sup>5'</sup>, R<sup>6'</sup>, R<sup>7'</sup> are not hydrogen;

Z is optionally substituted or unsubstituted acyl, -C(=O)NH<sub>2</sub>; -C(=W)-NH<sub>2</sub>; -C(=O)NHR<sup>2</sup>; -C(=W)NHR<sup>2</sup>; -C(=O)NR<sup>2</sup>R<sup>3</sup>; -C(=W)NR<sup>2</sup>R<sup>3</sup>; -C(=W)NH(CH<sub>2</sub>)<sub>n</sub>-(amino acid); an amino acid; -(CH<sub>2</sub>)<sub>n</sub>-(amino acid); -C(=O)R<sup>3</sup>; -C(=O)H; -C(=W)H; -C(=O)R<sup>2</sup>; -C(=W)R<sup>2</sup>; -C(=O)OR<sup>3</sup>; -C(=O)OH; -C(=W)OH; -C(=O)OR<sup>2</sup>; -C(=W)-OR<sup>2</sup>; -C(=O)-SH; -C(=W)SH; -C(=O)SR<sup>2</sup>; -C(=W)SR<sup>2</sup>; optionally substituted or unsubstituted branched or unbranched alkyl, alkenyl or alkynyl; CH<sub>3</sub>; CF<sub>3</sub>; vinyl

bromide;  $-\text{CR}^2\text{R}^2-\text{S}(\text{O})_n-\text{R}^3$ ;  $-\text{CR}^2\text{R}^2\text{NH}_2$ ;  $-\text{CR}^2\text{R}^2\text{NHR}^2$ ;  $-\text{CR}^2\text{R}^2\text{NR}^2\text{R}^3$ ;  $-\text{CR}^2\text{R}^2-\text{C}(=\text{O})\text{R}^2$ ;  $-\text{CN}$ ; or halo;

Y is O; S; or  $\text{S}(\text{O})_n$ ;

each W is independently O; S;  $-\text{NH}_2$ ;  $-\text{NHR}^2$ ;  $-\text{NR}^2\text{R}^2$ ;  $-\text{N-CN}$ ;  $-\text{N-NH}_2$ ;  $-\text{N-NHR}^2$ ;  $-\text{N-NR}^2\text{R}^3$ ;  $-\text{N-OH}$ ; or  $-\text{N-OR}^2$ ;

each  $\text{R}^2$  is independently hydrogen; an optionally substituted or unsubstituted branched or unbranched lower alkyl, alkenyl or alkynyl;  $\text{CH}_3$ ;  $\text{CF}_3$ ; or vinyl bromide;

each  $\text{R}^3$  is independently hydrogen; optionally substituted or unsubstituted branched or unbranched alkyl, alkenyl or alkynyl;  $\text{CH}_3$ ;  $\text{CF}_3$ ; vinyl bromide;  $-\text{CR}^2\text{R}^2-\text{S}(\text{O})_n-\text{R}^2$ ;  $-\text{CR}^2\text{R}^2\text{NH}_2$ ;  $-\text{CR}^2\text{R}^2\text{NHR}^2$ ;  $-\text{CR}^2\text{R}^2\text{NR}^2\text{R}^2$ ;  $-\text{CR}^2\text{R}^2-\text{C}(=\text{O})\text{R}^2$ ; optionally substituted or unsubstituted aryl; optionally substituted or unsubstituted heterocycle; optionally substituted or unsubstituted alkylaryl; optionally substituted or unsubstituted alkylheterocycle; optionally substituted or unsubstituted aralkyl; or optionally substituted or unsubstituted heterocycle-alkyl;

each n is independently 0, 1 or 2;


each p is independently 0, 1, 2, 3, 4 or 5; and

wherein the optionally substituted branched or unbranched alkyl, alkenyl, alkynyl, lower alkyl, lower alkenyl; lower alkynyl; acyl; aryl; heterocycle; alkaryl; alkheterocycle; arylalkyl; or alkylheterocycle optionally is substituted with one or more of halogen;  $-\text{OH}$ ;  $-\text{OR}^2$ ;  $-\text{SH}$ ;  $-\text{SR}^2$ ; oxime; hydrazine;  $-\text{C}(=\text{O})\text{H}$ ;  $-\text{C}(=\text{W})\text{H}$ ;  $-\text{C}(=\text{O})\text{R}^2$ ;  $-\text{C}(=\text{W})\text{R}^2$ ;  $-\text{C}(=\text{O})\text{OH}$ ;  $-\text{C}(=\text{W})\text{OH}$ ;  $-\text{C}(=\text{O})\text{OR}^2$ ;  $-\text{C}(=\text{W})\text{OR}^2$ ;  $-\text{C}(=\text{O})\text{SH}$ ;  $-\text{C}(=\text{W})\text{SH}$ ;  $-\text{C}(=\text{O})\text{SR}^2$ ;  $-\text{C}(=\text{W})\text{SR}^2$ ;  $-\text{C}(=\text{O})\text{NH}_2$ ;  $-\text{C}(=\text{W})\text{NH}_2$ ;  $-\text{C}(=\text{O})-\text{NHR}^2$ ;  $-\text{C}(=\text{W})\text{NHR}^2$ ;  $-\text{C}(=\text{O})\text{NR}^2\text{R}^3$ ;  $-\text{C}(=\text{W})-\text{NR}^2\text{R}^3$ ;  $-\text{NH}_2$ ;  $-\text{NHR}^2$ ;  $-\text{NR}^2\text{R}^3$ ;  $-\text{NHSO}_2-\text{C}_{1-3}\text{alkyl}$ ;  $-\text{NR}^2\text{SO}_2-\text{C}_{1-3}\text{alkyl}$ ;  $-\text{NHCO}-\text{C}_{1-3}\text{alkyl}$ ;  $-\text{NR}^2\text{CO}-\text{C}_{1-3}\text{alkyl}$ ;  $-\text{S}(\text{O})_n-\text{R}^3$ ;  $\text{C}_{1-3}$  alkoxy;  $\text{C}_{1-3}$ thioether; or an amino acid residue;

optionally in a pharmaceutically acceptable carrier or diluent.



Claim 24 (currently amended): A method for the treatment or prophylaxis of an HIV-infection in a host, wherein the HIV is resistant to one or more reverse transcriptase inhibitor(s), comprising administering to said host an effective anti-HIV treatment amount of a compound of ~~claim 1~~, formula (I):



or its a pharmaceutically acceptable salt thereof, wherein

R<sup>1</sup> is hydrogen; acyl; -C(=O)H; -C(=W)H; -C(=O)R<sup>2</sup>; -C(=W)R<sup>2</sup>; -C(=O)OH; -C(=W)OH; -C(=O)OR<sup>2</sup>; -C(=W)OR<sup>2</sup>; -C(=O)SH; -C(=W)SH; -C(=O)SR<sup>2</sup>; -C(=W)SR<sup>2</sup>; -C(=O)NH<sub>2</sub>; -C(=W)NH<sub>2</sub>; -C(=O)NHR<sup>2</sup>; -C(=W)NHR<sup>2</sup>; -C(=O)NR<sup>2</sup>R<sup>3</sup>; -C(=W)NR<sup>2</sup>R<sup>3</sup>; -C(=W)NH-(CH<sub>2</sub>)<sub>0</sub>-(amino acid); or -(CH<sub>2</sub>)<sub>0</sub>-(amino acid);

R<sup>4'</sup>, R<sup>5'</sup>, R<sup>6'</sup>, R<sup>7'</sup>, R<sup>2''</sup>, R<sup>3''</sup>, R<sup>4''</sup>, R<sup>5''</sup> and R<sup>6''</sup> are each independently H; halo; -NO<sub>2</sub>; -CN; -OH; -OR<sup>2</sup>; -SH; -SR<sup>2</sup>; -NH<sub>2</sub>; -NHR<sup>2</sup>; -NR<sup>2</sup>R<sup>3</sup>; -NHSO<sub>2</sub>-C<sub>1-3</sub>alkyl; -NR<sup>2</sup>SO<sub>2</sub>-C<sub>1-3</sub>alkyl; -NHCO-C<sub>1-3</sub>alkyl; -NR<sup>2</sup>CO-C<sub>1-3</sub>alkyl; optionally substituted or unsubstituted branched or unbranched alkyl, alkenyl or alkynyl; CH<sub>3</sub>; CF<sub>3</sub>; vinyl bromide; -CR<sup>2</sup>R<sup>2</sup>-S(O)<sub>0</sub>-R<sup>3</sup>; -CR<sup>2</sup>R<sup>2</sup>NH<sub>2</sub>; -CR<sup>2</sup>R<sup>2</sup>NHR<sup>2</sup>; -CR<sup>2</sup>R<sup>2</sup>NR<sup>2</sup>R<sup>3</sup>; -CR<sup>2</sup>R<sup>2</sup>-C(=O)R<sup>2</sup>; alkacyl; optionally substituted or unsubstituted acyl; -C(=O)H; -C(=W)H; -C(=O)R<sup>2</sup>; -C(=W)R<sup>2</sup>; -C(=O)OH; -C(=W)OH; -C(=O)OR<sup>2</sup>; -C(=W)OR<sup>2</sup>; -C(=O)-SH; -C(=W)SH; -C(=O)SR<sup>2</sup>; -C(=W)SR<sup>2</sup>; -C(=O)NH<sub>2</sub>; -C(=W)NH<sub>2</sub>; -C(=O)NHR<sup>2</sup>; -C(=W)NHR<sup>2</sup>; -C(=O)NR<sup>2</sup>R<sup>3</sup>; -C(=W)NR<sup>2</sup>R<sup>3</sup>; -C(=W)NH(CH<sub>2</sub>)<sub>0</sub>-(amino acid); an amino acid; or -(CH<sub>2</sub>)<sub>0</sub>(amino acid);

wherein if R<sup>5'</sup> is hydrogen, F, Cl, Br, -NO<sub>2</sub>, -CN, -OR<sup>2</sup>, -NR<sup>2</sup>R<sup>2</sup>, -NHSO<sub>2</sub>-C<sub>1-3</sub>alkyl; or -NHCO-C<sub>1-3</sub>alkyl, then at least one of R<sup>4'</sup>, R<sup>6'</sup> and R<sup>7'</sup> is not hydrogen; or alternatively, wherein at least two of R<sup>4'</sup>, R<sup>5'</sup>, R<sup>6'</sup>, R<sup>7'</sup> are not hydrogen;

Z is optionally substituted or unsubstituted acyl, -C(=O)NH<sub>2</sub>; -C(=W)-NH<sub>2</sub>; -C(=O)NHR<sup>2</sup>; -C(=W)NHR<sup>2</sup>; -C(=O)NR<sup>2</sup>R<sup>3</sup>; -C(=W)NR<sup>2</sup>R<sup>3</sup>; -C(=W)NH(CH<sub>2</sub>)<sub>0</sub>-(amino acid); an amino acid; -(CH<sub>2</sub>)<sub>0</sub>-(amino acid); -C(=O)R<sup>3</sup>; -C(=O)H; -C(=W)H; -C(=O)R<sup>2</sup>; -C(=W)R<sup>2</sup>; -C(=O)OR<sup>3</sup>; -C(=O)OH; -C(=W)OH; -C(=O)OR<sup>2</sup>; -C(=W)-OR<sup>2</sup>; -C(=O)-SH; -C(=W)SH; -C(=O)SR<sup>2</sup>; -C(=W)SR<sup>2</sup>; optionally substituted or unsubstituted branched or unbranched alkyl, alkenyl or alkynyl; CH<sub>3</sub>; CF<sub>3</sub>; vinyl

bromide;  $-\text{CR}^2\text{R}^2-\text{S}(\text{O})_n-\text{R}^3$ ;  $-\text{CR}^2\text{R}^2\text{NH}_2$ ;  $-\text{CR}^2\text{R}^2\text{NHR}^2$ ;  $-\text{CR}^2\text{R}^2\text{NR}^2\text{R}^3$ ;  $-\text{CR}^2\text{R}^2-\text{C}(=\text{O})\text{R}^2$ ;  $-\text{CN}$ ; or halo;

Y is O; S; or  $\text{S}(\text{O})_n$ ;

each W is independently O; S;  $-\text{NH}_2$ ;  $-\text{NHR}^2$ ;  $-\text{NR}^2\text{R}^2$ ;  $-\text{N-CN}$ ;  $-\text{N-NH}_2$ ;  $-\text{N-NHR}^2$ ;  $-\text{N-NR}^2\text{R}^3$ ;  $-\text{N-OH}$ ; or  $-\text{N-OR}^2$ ;

each  $\text{R}^2$  is independently hydrogen; an optionally substituted or unsubstituted branched or unbranched lower alkyl, alkenyl or alkynyl;  $\text{CH}_3$ ;  $\text{CF}_3$ ; or vinyl bromide;

each  $\text{R}^3$  is independently hydrogen; optionally substituted or unsubstituted branched or unbranched alkyl, alkenyl or alkynyl;  $\text{CH}_3$ ;  $\text{CF}_3$ ; vinyl bromide;  $-\text{CR}^2\text{R}^2-\text{S}(\text{O})_n-\text{R}^2$ ;  $-\text{CR}^2\text{R}^2\text{NH}_2$ ;  $-\text{CR}^2\text{R}^2\text{NHR}^2$ ;  $-\text{CR}^2\text{R}^2\text{NR}^2\text{R}^2$ ;  $-\text{CR}^2\text{R}^2-\text{C}(=\text{O})\text{R}^2$ ; optionally substituted or unsubstituted aryl; optionally substituted or unsubstituted heterocycle; optionally substituted or unsubstituted alkylaryl; optionally substituted or unsubstituted alkylheterocycle; optionally substituted or unsubstituted aralkyl; or optionally substituted or unsubstituted heterocycle-alkyl;


each n is independently 0, 1 or 2;

each p is independently 0, 1, 2, 3, 4 or 5; and

wherein the optionally substituted branched or unbranched alkyl, alkenyl, alkynyl, lower alkyl, lower alkenyl; lower alkynyl; acyl; aryl; heterocycle; alkaryl; alkheterocycle; arylalkyl; or alkylheterocycle optionally is substituted with one or more of: halogen;  $-\text{OH}$ ;  $-\text{OR}^2$ ;  $-\text{SH}$ ;  $-\text{SR}^2$ ; oxime; hydrazine;  $-\text{C}(=\text{O})\text{H}$ ;  $-\text{C}(=\text{W})\text{H}$ ;  $-\text{C}(=\text{O})\text{R}^2$ ;  $-\text{C}(=\text{W})\text{R}^2$ ;  $-\text{C}(=\text{O})\text{OH}$ ;  $-\text{C}(=\text{W})\text{OH}$ ;  $-\text{C}(=\text{O})\text{OR}^2$ ;  $-\text{C}(=\text{W})\text{OR}^2$ ;  $-\text{C}(=\text{O})\text{SH}$ ;  $-\text{C}(=\text{W})\text{SH}$ ;  $-\text{C}(=\text{O})\text{SR}^2$ ;  $-\text{C}(=\text{W})\text{SR}^2$ ;  $-\text{C}(=\text{O})\text{NH}_2$ ;  $-\text{C}(=\text{W})\text{NH}_2$ ;  $-\text{C}(=\text{O})-\text{NHR}^2$ ;  $-\text{C}(=\text{W})\text{NHR}^2$ ;  $-\text{C}(=\text{O})\text{NR}^2\text{R}^3$ ;  $-\text{C}(=\text{W})-\text{NR}^2\text{R}^3$ ;  $-\text{NH}_2$ ;  $-\text{NHR}^2$ ;  $-\text{NR}^2\text{R}^3$ ;  $-\text{NHSO}_2-\text{C}_{1-3}\text{alkyl}$ ;  $-\text{NR}^2\text{SO}_2-\text{C}_{1-3}\text{alkyl}$ ;  $-\text{NHCO}-\text{C}_{1-3}\text{alkyl}$ ;  $-\text{NR}^2\text{CO}-\text{C}_{1-3}\text{alkyl}$ ;  $-\text{S}(\text{O})_n-\text{R}^3$ ;  $\text{C}_{1-3}$  alkoxy;  $\text{C}_{1-3}$ thioether; or an amino acid residue;

in combination and/or alternation with one or more other anti-HIV agent, optionally in a pharmaceutically acceptable carrier or diluent.

Claim 25 (currently amended): A method for salvage therapy in the treatment or prophylaxis of an HIV-infection in a host, comprising administering to said host an effective anti-HIV treatment amount of a compound of ~~claim 1~~, formula (I):



or its a pharmaceutically acceptable salt thereof, wherein

R¹ is hydrogen; acyl; -C(=O)H; -C(=W)H; -C(=O)R²; -C(=W)R²; -C(=O)OH; -C(=W)OH; -C(=O)OR²; -C(=W)OR²; -C(=O)SH; -C(=W)SH; -C(=O)SR²; -C(=W)SR²; -C(=O)NH₂; -C(=W)NH₂; -C(=O)NHR²; -C(=W)NHR²; -C(=O)NR²R³; -C(=W)NR²R³; -C(=W)NH-(CH₂)<sub>p</sub>-(amino acid); or -(CH₂)<sub>p</sub>-(amino acid);

R⁴, R⁵, R⁶, R⁷, R², R³, R⁴, R⁵ and R⁶ are each independently H; halo; -NO₂; -CN; -OH; -OR²; -SH; -SR²; -NH₂; -NHR²; -NR²R³; -NHSO₂-C₁-₃alkyl; -NR²SO₂-C₁-₃alkyl; -NHCO-C₁-₃alkyl; -NR²CO-C₁-₃alkyl; optionally substituted or unsubstituted branched or unbranched alkyl, alkenyl or alkynyl; CH₃; CF₃; vinyl bromide; -CR²R²-S(O)<sub>p</sub>-R³; -CR²R²NH₂; -CR²R²NHR²; -CR²R²NR²R³; -CR²R²-C(=O)R²; alkacyl; optionally substituted or unsubstituted acyl; -C(=O)H; -C(=W)H; -C(=O)R²; -C(=W)R²; -C(=O)OH; -C(=W)OH; -C(=O)OR²; -C(=W)OR²; -C(=O)SH; -C(=W)SH; -C(=O)SR²; -C(=W)SR²; -C(=O)NH₂; -C(=W)NH₂; -C(=O)NHR²; -C(=W)NHR²; -C(=O)NR²R³; -C(=W)NR²R³; -C(=W)NH(CH₂)<sub>p</sub>-(amino acid); an amino acid; or -(CH₂)<sub>p</sub>(amino acid);

wherein if R⁵ is hydrogen, F, Cl, Br, -NO₂, -CN, -OR², -NR²R², -NHSO₂-C₁-₃alkyl; or -NHCO-C₁-₃alkyl, then at least one of R⁴, R⁶ and R⁷ is not hydrogen; or alternatively, wherein at least two of R⁴, R⁵, R⁶, R⁷ are not hydrogen;

Z is optionally substituted or unsubstituted acyl; -C(=O)NH₂; -C(=W)-NH₂; -C(=O)NHR²; -C(=W)NHR²; -C(=O)NR²R³; -C(=W)NR²R³; -C(=W)NH(CH₂)<sub>p</sub>-(amino acid); an amino acid; -(CH₂)<sub>p</sub>-(amino acid); -C(=O)R³; -C(=O)H; -C(=W)H; -C(=O)R²; -C(=W)R²; -C(=O)OR³; -C(=O)OH; -C(=W)OH; -C(=O)OR²; -C(=W)OR²; -C(=O)-SH; -C(=W)SH; -C(=O)SR²; -C(=W)SR²; optionally substituted or unsubstituted branched or unbranched alkyl, alkenyl or alkynyl; CH₃; CF₃; vinyl

bromide;  $-\text{CR}^2\text{R}^2-\text{S}(\text{O})_n-\text{R}^3$ ;  $-\text{CR}^2\text{R}^2\text{NH}_2$ ;  $-\text{CR}^2\text{R}^2\text{NHR}^2$ ;  $-\text{CR}^2\text{R}^2\text{NR}^2\text{R}^3$ ;  $-\text{CR}^2\text{R}^2-\text{C}(=\text{O})\text{R}^2$ ;  $-\text{CN}$ ; or halo;

Y is O; S; or  $\text{S}(\text{O})_n$ ;

each W is independently O; S;  $-\text{NH}_2$ ;  $-\text{NHR}^2$ ;  $-\text{NR}^2\text{R}^2$ ;  $-\text{N-CN}$ ;  $-\text{N-NH}_2$ ;  $-\text{N-NHR}^2$ ;  $-\text{N-NR}^2\text{R}^3$ ;  $-\text{N-OH}$ ; or  $-\text{N-OR}^2$ ;

each  $\text{R}^2$  is independently hydrogen; an optionally substituted or unsubstituted branched or unbranched lower alkyl, alkenyl or alkynyl;  $\text{CH}_3$ ;  $\text{CF}_3$ ; or vinyl bromide;

each  $\text{R}^3$  is independently hydrogen; optionally substituted or unsubstituted branched or unbranched alkyl, alkenyl or alkynyl;  $\text{CH}_3$ ;  $\text{CF}_3$ ; vinyl bromide;  $-\text{CR}^2\text{R}^2-\text{S}(\text{O})_n-\text{R}^2$ ;  $-\text{CR}^2\text{R}^2\text{NH}_2$ ;  $-\text{CR}^2\text{R}^2\text{NHR}^2$ ;  $-\text{CR}^2\text{R}^2\text{NR}^2\text{R}^2$ ;  $-\text{CR}^2\text{R}^2-\text{C}(=\text{O})\text{R}^2$ ; optionally substituted or unsubstituted aryl; optionally substituted or unsubstituted heterocycle; optionally substituted or unsubstituted alkylaryl; optionally substituted or unsubstituted alkylheterocycle; optionally substituted or unsubstituted aralkyl; or optionally substituted or unsubstituted heterocycle-alkyl;


each n is independently 0, 1 or 2;

each p is independently 0, 1, 2, 3, 4 or 5; and

wherein the optionally substituted branched or unbranched alkyl, alkenyl, alkynyl, lower alkyl, lower alkenyl; lower alkynyl; acyl; aryl; heterocycle; alkaryl; alkheterocycle; arylalkyl; or alkylheterocycle optionally is substituted with one or more of halogen;  $-\text{OH}$ ;  $-\text{OR}^2$ ;  $-\text{SH}$ ;  $-\text{SR}^2$ ; oxime; hydrazine;  $-\text{C}(=\text{O})\text{H}$ ;  $-\text{C}(=\text{W})\text{H}$ ;  $-\text{C}(=\text{O})\text{R}^2$ ;  $-\text{C}(=\text{W})\text{R}^2$ ;  $-\text{C}(=\text{O})\text{OH}$ ;  $-\text{C}(=\text{W})\text{OH}$ ;  $-\text{C}(=\text{O})\text{OR}^2$ ;  $-\text{C}(=\text{W})\text{OR}^2$ ;  $-\text{C}(=\text{O})\text{SH}$ ;  $-\text{C}(=\text{W})\text{SH}$ ;  $-\text{C}(=\text{O})\text{SR}^2$ ;  $-\text{C}(=\text{W})\text{SR}^2$ ;  $-\text{C}(=\text{O})\text{NH}_2$ ;  $-\text{C}(=\text{W})\text{NH}_2$ ;  $-\text{C}(=\text{O})-\text{NHR}^2$ ;  $-\text{C}(=\text{W})\text{NHR}^2$ ;  $-\text{C}(=\text{O})\text{NR}^2\text{R}^3$ ;  $-\text{C}(=\text{W})-\text{NR}^2\text{R}^3$ ;  $-\text{NH}_2$ ;  $-\text{NHR}^2$ ;  $-\text{NR}^2\text{R}^3$ ;  $-\text{NHSO}_2-\text{C}_{1-3}\text{alkyl}$ ;  $-\text{NR}^2\text{SO}_2-\text{C}_{1-3}\text{alkyl}$ ;  $-\text{NHCO}-\text{C}_{1-3}\text{alkyl}$ ;  $-\text{NR}^2\text{CO}-\text{C}_{1-3}\text{alkyl}$ ;  $-\text{S}(\text{O})_n-\text{R}^3$ ;  $\text{C}_{1-3}$  alkoxy;  $\text{C}_{1-3}$ thioether; or an amino acid residue;

optionally in a pharmaceutically acceptable carrier or diluent.

Claim 26 (currently amended): A method for salvage therapy in the treatment or prophylaxis of an HIV-infection in a host, comprising administering to said host an effective anti-HIV treatment amount of a compound of ~~claim 1~~, formula (I):



or its a pharmaceutically acceptable salt thereof, wherein

R¹ is hydrogen; acyl; -C(=O)H; -C(=W)H; -C(=O)R²; -C(=W)R²; -C(=O)OH; -C(=W)OH; -C(=O)OR²; -C(=W)OR²; -C(=O)SH; -C(=W)SH; -C(=O)SR²; -C(=W)SR²; -C(=O)NH₂; -C(=W)NH₂; -C(=O)NHR²; -C(=W)NHR²; -C(=O)NR²R³; -C(=W)NR²R³; -C(=W)NH-(CH₂)<sub>p</sub>-(amino acid); or -(CH₂)<sub>p</sub>-(amino acid);

R⁴, R⁵, R⁶, R⁷, R², R³, R⁴, R⁵ and R⁶ are each independently H; halo; -NO₂; -CN; -OH; -OR²; -SH; -SR²; -NH₂; -NHR²; -NR²R³; -NHSO₂-C₁-₃alkyl; -NR²SO₂-C₁-₃alkyl; -NHCO-C₁-₃alkyl; -NR²CO-C₁-₃alkyl; optionally substituted or unsubstituted branched or unbranched alkyl, alkenyl or alkynyl; CH₃; CF₃; vinyl bromide; -CR²R²-S(O)<sub>p</sub>-R³; -CR²R²NH₂; -CR²R²NHR²; -CR²R²NR²R³; -CR²R²-C(=O)R²; alkacyl; optionally substituted or unsubstituted acyl; -C(=O)H; -C(=W)H; -C(=O)R²; -C(=W)R²; -C(=O)OH; -C(=W)OH; -C(=O)OR²; -C(=W)OR²; -C(=O)SH; -C(=W)SH; -C(=O)SR²; -C(=W)SR²; -C(=O)NH₂; -C(=W)NH₂; -C(=O)NHR²; -C(=W)NHR²; -C(=O)NR²R³; -C(=W)NR²R³; -C(=W)NH-(CH₂)<sub>p</sub>-(amino acid); an amino acid; or -(CH₂)<sub>p</sub>(amino acid);

wherein if R⁵ is hydrogen, F, Cl, Br, -NO₂, -CN, -OR², -NR²R², -NHSO₂-C₁-₃alkyl; or -NHCO-C₁-₃alkyl, then at least one of R⁴, R⁶ and R⁷ is not hydrogen; or alternatively, wherein at least two of R⁴, R⁵, R⁶, R⁷ are not hydrogen;

Z is optionally substituted or unsubstituted acyl, -C(=O)NH₂; -C(=W)-NH₂; -C(=O)NHR²; -C(=W)NHR²; -C(=O)NR²R³; -C(=W)NR²R³; -C(=W)NH-(CH₂)<sub>p</sub>-(amino acid); an amino acid; -(CH₂)<sub>p</sub>-(amino acid); -C(=O)R³; -C(=O)H; -C(=W)H; -C(=O)R²; -C(=W)R²; -C(=O)OR³; -C(=O)OH; -C(=W)OH; -C(=O)OR²; -C(=W)OR²; -C(=O)-SH; -C(=W)SH; -C(=O)SR²; -C(=W)SR²; optionally substituted or unsubstituted branched or unbranched alkyl, alkenyl or alkynyl; CH₃; CF₃; vinyl

bromide;  $-\text{CR}^2\text{R}^2-\text{S}(\text{O})_n-\text{R}^3$ ;  $-\text{CR}^2\text{R}^2\text{NH}_2$ ;  $-\text{CR}^2\text{R}^2\text{NHR}^2$ ;  $-\text{CR}^2\text{R}^2\text{NR}^2\text{R}^3$ ;  $-\text{CR}^2\text{R}^2-\text{C}(=\text{O})\text{R}^2$ ;  $-\text{CN}$ ; or halo;

Y is O; S; or  $\text{S}(\text{O})_n$ ;

each W is independently O; S;  $-\text{NH}_2$ ;  $-\text{NHR}^2$ ;  $-\text{NR}^2\text{R}^2$ ;  $-\text{N-CN}$ ;  $-\text{N-NH}_2$ ;  $-\text{N-NHR}^2$ ;  $-\text{N-NR}^2\text{R}^3$ ;  $-\text{N-OH}$ ; or  $-\text{N-OR}^2$ ;

each  $\text{R}^2$  is independently hydrogen; an optionally substituted or unsubstituted branched or unbranched lower alkyl, alkenyl or alkynyl;  $\text{CH}_3$ ;  $\text{CF}_3$ ; or vinyl bromide;

each  $\text{R}^3$  is independently hydrogen; optionally substituted or unsubstituted branched or unbranched alkyl, alkenyl or alkynyl;  $\text{CH}_3$ ;  $\text{CF}_3$ ; vinyl bromide;  $-\text{CR}^2\text{R}^2-\text{S}(\text{O})_n-\text{R}^2$ ;  $-\text{CR}^2\text{R}^2\text{NH}_2$ ;  $-\text{CR}^2\text{R}^2\text{NHR}^2$ ;  $-\text{CR}^2\text{R}^2\text{NR}^2\text{R}^2$ ;  $-\text{CR}^2\text{R}^2-\text{C}(=\text{O})\text{R}^2$ ; optionally substituted or unsubstituted aryl; optionally substituted or unsubstituted heterocycle; optionally substituted or unsubstituted alkylaryl; optionally substituted or unsubstituted alkylheterocycle; optionally substituted or unsubstituted aralkyl; or optionally substituted or unsubstituted heterocycle-alkyl;


each n is independently 0, 1 or 2;

each p is independently 0, 1, 2, 3, 4 or 5; and

wherein the optionally substituted branched or unbranched alkyl, alkenyl, alkynyl, lower alkyl, lower alkenyl; lower alkynyl; acyl; aryl; heterocycle; alkaryl; alkheterocycle; arylalkyl; or alkylheterocycle optionally is substituted with one or more of halogen;  $-\text{OH}$ ;  $-\text{OR}^2$ ;  $-\text{SH}$ ;  $-\text{SR}^2$ ; oxime; hydrazine;  $-\text{C}(=\text{O})\text{H}$ ;  $-\text{C}(=\text{W})\text{H}$ ;  $-\text{C}(=\text{O})\text{R}^2$ ;  $-\text{C}(=\text{W})\text{R}^2$ ;  $-\text{C}(=\text{O})\text{OH}$ ;  $-\text{C}(=\text{W})\text{OH}$ ;  $-\text{C}(=\text{O})\text{OR}^2$ ;  $-\text{C}(=\text{W})\text{OR}^2$ ;  $-\text{C}(=\text{O})\text{SH}$ ;  $-\text{C}(=\text{W})\text{SH}$ ;  $-\text{C}(=\text{O})\text{SR}^2$ ;  $-\text{C}(=\text{W})\text{SR}^2$ ;  $-\text{C}(=\text{O})\text{NH}_2$ ;  $-\text{C}(=\text{W})\text{NH}_2$ ;  $-\text{C}(=\text{O})-\text{NHR}^2$ ;  $-\text{C}(=\text{W})\text{NHR}^2$ ;  $-\text{C}(=\text{O})\text{NR}^2\text{R}^3$ ;  $-\text{C}(=\text{W})-\text{NR}^2\text{R}^3$ ;  $-\text{NH}_2$ ;  $-\text{NHR}^2$ ;  $-\text{NR}^2\text{R}^3$ ;  $-\text{NHSO}_2-\text{C}_{1-3}\text{alkyl}$ ;  $-\text{NR}^2\text{SO}_2-\text{C}_{1-3}\text{alkyl}$ ;  $-\text{NHCO}-\text{C}_{1-3}\text{alkyl}$ ;  $-\text{NR}^2\text{CO}-\text{C}_{1-3}\text{alkyl}$ ;  $-\text{S}(\text{O})_n-\text{R}^3$ ;  $\text{C}_{1-3}$  alkoxy;  $\text{C}_{1-3}$ thioether; or an amino acid residue;

in combination and/or alternation with one or more other anti-HIV agent, optionally in a pharmaceutically acceptable carrier or diluent.

Claim 27 (currently amended): A method for the treatment or prophylaxis of an HIV-infection in a host, wherein the HIV is resistant to one or more reverse transcriptase inhibitor(s), comprising administering to said host an effective anti-HIV treatment amount of a compound of ~~claim 1~~, formula (I):



or its a pharmaceutically acceptable salt thereof, wherein

R¹ is hydrogen; acyl; -C(=O)H; -C(=W)H; -C(=O)R²; -C(=W)R²; -C(=O)OH; -C(=W)OH; -C(=O)OR²; -C(=W)OR²; -C(=O)SH; -C(=W)SH; -C(=O)SR²; -C(=W)SR²; -C(=O)NH₂; -C(=W)NH₂; -C(=O)NHR²; -C(=W)NHR²; -C(=O)NR²R³; -C(=W)NR²R³; -C(=W)NH-(CH₂)<sub>p</sub>-(amino acid); or -(CH₂)<sub>p</sub>-(amino acid);

R⁴, R⁵, R⁶, R⁷, R², R³, R⁴, R⁵ and R⁶ are each independently H; halo; -NO₂; -CN; -OH; -OR²; -SH; -SR²; -NH₂; -NHR²; -NR²R³; -NHSO₂-C₁-₃alkyl; -NR²SO₂-C₁-₃alkyl; -NHCO-C₁-₃alkyl; -NR²CO-C₁-₃alkyl; optionally substituted or unsubstituted branched or unbranched alkyl, alkenyl or alkynyl; CH₃; CF₃; vinyl bromide; -CR²R²-S(O)<sub>p</sub>-R³; -CR²R²NH₂; -CR²R²NHR²; -CR²R²NR²R³; -CR²R²-C(=O)R²; alkacyl; optionally substituted or unsubstituted acyl; -C(=O)H; -C(=W)H; -C(=O)R²; -C(=W)R²; -C(=O)OH; -C(=W)OH; -C(=O)OR²; -C(=W)OR²; -C(=O)SH; -C(=W)SH; -C(=O)SR²; -C(=W)SR²; -C(=O)NH₂; -C(=W)NH₂; -C(=O)NHR²; -C(=W)NHR²; -C(=O)NR²R³; -C(=W)NR²R³; -C(=W)NH(CH₂)<sub>p</sub>-(amino acid); an amino acid; or -(CH₂)<sub>p</sub>(amino acid);

wherein if R⁵ is hydrogen, F, Cl, Br, -NO₂, -CN, -OR², -NR²R², -NHSO₂-C₁-₃alkyl; or -NHCO-C₁-₃alkyl, then at least one of R⁴, R⁶ and R⁷ is not hydrogen; or alternatively, wherein at least two of R⁴, R⁵, R⁶, R⁷ are not hydrogen;

Z is optionally substituted or unsubstituted acyl, -C(=O)NH₂; -C(=W)-NH₂; -C(=O)NHR²; -C(=W)NHR²; -C(=O)NR²R³; -C(=W)NR²R³; -C(=W)NH(CH₂)<sub>p</sub>-(amino acid); an amino acid; -(CH₂)<sub>p</sub>-(amino acid); -C(=O)R³; -C(=O)H; -C(=W)H; -C(=O)R²; -C(=W)R²; -C(=O)OR³; -C(=O)OH; -C(=W)OH; -C(=O)OR²; -C(=W)OR²; -C(=O)-SH; -C(=W)SH; -C(=O)SR²; -C(=W)SR²; optionally substituted or unsubstituted branched or unbranched alkyl, alkenyl or alkynyl; CH₃; CF₃; vinyl

bromide;  $-\text{CR}^2\text{R}^2-\text{S}(\text{O})_n-\text{R}^3$ ;  $-\text{CR}^2\text{R}^2\text{NH}_2$ ;  $-\text{CR}^2\text{R}^2\text{NHR}^2$ ;  $-\text{CR}^2\text{R}^2\text{NR}^2\text{R}^3$ ;  $-\text{CR}^2\text{R}^2-\text{C}(=\text{O})\text{R}^2$ ;  $-\text{CN}$ ; or halo;

Y is O; S; or  $\text{S}(\text{O})_n$ ;

each W is independently O; S;  $-\text{NH}_2$ ;  $-\text{NHR}^2$ ;  $-\text{NR}^2\text{R}^2$ ;  $-\text{N-CN}$ ;  $-\text{N-NH}_2$ ;  $-\text{N-NHR}^2$ ;  $-\text{N-NR}^2\text{R}^3$ ;  $-\text{N-OH}$ ; or  $-\text{N-OR}^2$ ;

each  $\text{R}^2$  is independently hydrogen; an optionally substituted or unsubstituted branched or unbranched lower alkyl, alkenyl or alkynyl;  $\text{CH}_3$ ;  $\text{CF}_3$ ; or vinyl bromide;

each  $\text{R}^3$  is independently hydrogen; optionally substituted or unsubstituted branched or unbranched alkyl, alkenyl or alkynyl;  $\text{CH}_3$ ;  $\text{CF}_3$ ; vinyl bromide;  $-\text{CR}^2\text{R}^2-\text{S}(\text{O})_n-\text{R}^2$ ;  $-\text{CR}^2\text{R}^2\text{NH}_2$ ;  $-\text{CR}^2\text{R}^2\text{NHR}^2$ ;  $-\text{CR}^2\text{R}^2\text{NR}^2\text{R}^2$ ;  $-\text{CR}^2\text{R}^2-\text{C}(=\text{O})\text{R}^2$ ; optionally substituted or unsubstituted aryl; optionally substituted or unsubstituted heterocycle; optionally substituted or unsubstituted alkylaryl; optionally substituted or unsubstituted alkylheterocycle; optionally substituted or unsubstituted aralkyl; or optionally substituted or unsubstituted heterocycle-alkyl;

each n is independently 0, 1 or 2;


each p is independently 0, 1, 2, 3, 4 or 5; and

wherein the optionally substituted branched or unbranched alkyl, alkenyl, alkynyl, lower alkyl, lower alkenyl; lower alkynyl; acyl; aryl; heterocycle; alkaryl; alkheterocycle; arylalkyl; or alkylheterocycle optionally is substituted with one or more of halogen;  $-\text{OH}$ ;  $-\text{OR}^2$ ;  $-\text{SH}$ ;  $-\text{SR}^2$ ; oxime; hydrazine;  $-\text{C}(=\text{O})\text{H}$ ;  $-\text{C}(=\text{W})\text{H}$ ;  $-\text{C}(=\text{O})\text{R}^2$ ;  $-\text{C}(=\text{W})\text{R}^2$ ;  $-\text{C}(=\text{O})\text{OH}$ ;  $-\text{C}(=\text{W})\text{OH}$ ;  $-\text{C}(=\text{O})\text{OR}^2$ ;  $-\text{C}(=\text{W})\text{OR}^2$ ;  $-\text{C}(=\text{O})\text{SH}$ ;  $-\text{C}(=\text{W})\text{SH}$ ;  $-\text{C}(=\text{O})\text{SR}^2$ ;  $-\text{C}(=\text{W})\text{SR}^2$ ;  $-\text{C}(=\text{O})\text{NH}_2$ ;  $-\text{C}(=\text{W})\text{NH}_2$ ;  $-\text{C}(=\text{O})-\text{NHR}^2$ ;  $-\text{C}(=\text{W})\text{NHR}^2$ ;  $-\text{C}(=\text{O})\text{NR}^2\text{R}^3$ ;  $-\text{C}(=\text{W})-\text{NR}^2\text{R}^3$ ;  $-\text{NH}_2$ ;  $-\text{NHR}^2$ ;  $-\text{NR}^2\text{R}^3$ ;  $-\text{NHSO}_2-\text{C}_{1-3}\text{alkyl}$ ;  $-\text{NR}^2\text{SO}_2-\text{C}_{1-3}\text{alkyl}$ ;  $-\text{NHCO}-\text{C}_{1-3}\text{alkyl}$ ;  $-\text{NR}^2\text{CO}-\text{C}_{1-3}\text{alkyl}$ ;  $-\text{S}(\text{O})_n-\text{R}^3$ ;  $\text{C}_{1-3}$  alkoxy;  $\text{C}_{1-3}$ thioether; or an amino acid residue;

optionally in a pharmaceutically acceptable carrier or diluent.



Claim 28 (currently amended): A method for the treatment or prophylaxis of an HIV-infection in a host, wherein the HIV has a mutation at lysine 103 → asparagine and/or tyrosine 181 → cysteine in HIV reverse transcriptase, comprising administering to said host an effective anti-HIV treatment amount of a compound of ~~claim 1~~, formula (I):



or its a pharmaceutically acceptable salt thereof, wherein

R<sup>1</sup> is hydrogen; acyl; -C(=O)H; -C(=W)H; -C(=O)R<sup>2</sup>; -C(=W)R<sup>2</sup>; -C(=O)OH; -C(=W)OH; -C(=O)OR<sup>2</sup>; -C(=W)OR<sup>2</sup>; -C(=O)SH; -C(=W)SH; -C(=O)SR<sup>2</sup>; -C(=W)SR<sup>2</sup>; -C(=O)NH<sub>2</sub>; -C(=W)NH<sub>2</sub>; -C(=O)NHR<sup>2</sup>; -C(=W)NHR<sup>2</sup>; -C(=O)NR<sup>2</sup>R<sup>3</sup>; -C(=W)NR<sup>2</sup>R<sup>3</sup>; -C(=W)NH-(CH<sub>2</sub>)<sub>p</sub>-(amino acid); or -(CH<sub>2</sub>)<sub>p</sub>-(amino acid);

R<sup>4'</sup>, R<sup>5'</sup>, R<sup>6'</sup>, R<sup>7'</sup>, R<sup>2''</sup>, R<sup>3''</sup>, R<sup>4''</sup>, R<sup>5''</sup> and R<sup>6''</sup> are each independently H; halo; -NO<sub>2</sub>; -CN; -OH; -OR<sup>2</sup>; -SH; -SR<sup>2</sup>; -NH<sub>2</sub>; -NHR<sup>2</sup>; -NR<sup>2</sup>R<sup>3</sup>; -NHSO<sub>2</sub>-C<sub>1-3</sub>alkyl; -NR<sup>2</sup>SO<sub>2</sub>-C<sub>1-3</sub>alkyl; -NHCO-C<sub>1-3</sub>alkyl; -NR<sup>2</sup>CO-C<sub>1-3</sub>alkyl; optionally substituted or unsubstituted branched or unbranched alkyl, alkenyl or alkynyl; CH<sub>3</sub>; CF<sub>3</sub>; vinyl bromide; -CR<sup>2</sup>R<sup>2</sup>-S(O)<sub>p</sub>-R<sup>3</sup>; -CR<sup>2</sup>R<sup>2</sup>NH<sub>2</sub>; -CR<sup>2</sup>R<sup>2</sup>NHR<sup>2</sup>; -CR<sup>2</sup>R<sup>2</sup>NR<sup>2</sup>R<sup>3</sup>; -CR<sup>2</sup>R<sup>2</sup>-C(=O)R<sup>2</sup>; alkacyl; optionally substituted or unsubstituted acyl; -C(=O)H; -C(=W)H; -C(=O)R<sup>2</sup>; -C(=W)R<sup>2</sup>; -C(=O)OH; -C(=W)OH; -C(=O)OR<sup>2</sup>; -C(=W)OR<sup>2</sup>; -C(=O)-SH; -C(=W)SH; -C(=O)SR<sup>2</sup>; -C(=W)SR<sup>2</sup>; -C(=O)NH<sub>2</sub>; -C(=W)NH<sub>2</sub>; -C(=O)NHR<sup>2</sup>; -C(=W)NHR<sup>2</sup>; -C(=O)NR<sup>2</sup>R<sup>3</sup>; -C(=W)NR<sup>2</sup>R<sup>3</sup>; -C(=W)NH(CH<sub>2</sub>)<sub>p</sub>-(amino acid); an amino acid; or -(CH<sub>2</sub>)<sub>p</sub>(amino acid);

wherein if R<sup>5'</sup> is hydrogen, F, Cl, Br, -NO<sub>2</sub>, -CN, -OR<sup>2</sup>, -NR<sup>2</sup>R<sup>2</sup>, -NHSO<sub>2</sub>-C<sub>1-3</sub>alkyl; or -NHCO-C<sub>1-3</sub>alkyl, then at least one of R<sup>4'</sup>, R<sup>6'</sup> and R<sup>7'</sup> is not hydrogen; or alternatively, wherein at least two of R<sup>4'</sup>, R<sup>5'</sup>, R<sup>6'</sup>, R<sup>7'</sup> are not hydrogen;

Z is optionally substituted or unsubstituted acyl, -C(=O)NH<sub>2</sub>; -C(=W)-NH<sub>2</sub>; -C(=O)NHR<sup>2</sup>; -C(=W)NHR<sup>2</sup>; -C(=O)NR<sup>2</sup>R<sup>3</sup>; -C(=W)NR<sup>2</sup>R<sup>3</sup>; -C(=W)NH(CH<sub>2</sub>)<sub>p</sub>-(amino acid); an amino acid; -(CH<sub>2</sub>)<sub>p</sub>-(amino acid); -C(=O)R<sup>3</sup>; -C(=O)H; -C(=W)H; -C(=O)R<sup>2</sup>; -C(=W)R<sup>2</sup>; -C(=O)OR<sup>3</sup>; -C(=O)OH; -C(=W)OH; -C(=O)OR<sup>2</sup>; -C(=W)-OR<sup>2</sup>; -C(=O)-SH; -C(=W)SH; -C(=O)SR<sup>2</sup>; -C(=W)SR<sup>2</sup>; optionally substituted or unsubstituted branched or unbranched alkyl, alkenyl or alkynyl; CH<sub>3</sub>; CF<sub>3</sub>; vinyl

bromide;  $-\text{CR}^2\text{R}^2-\text{S}(\text{O})_n-\text{R}^3$ ;  $-\text{CR}^2\text{R}^2\text{NH}_2$ ;  $-\text{CR}^2\text{R}^2\text{NHR}^2$ ;  $-\text{CR}^2\text{R}^2\text{NR}^2\text{R}^3$ ;  $-\text{CR}^2\text{R}^2-\text{C}(=\text{O})\text{R}^2$ ;  $-\text{CN}$ ; or halo;

Y is O; S; or  $\text{S}(\text{O})_n$ ;

each W is independently O; S;  $-\text{NH}_2$ ;  $-\text{NHR}^2$ ;  $-\text{NR}^2\text{R}^2$ ;  $-\text{N-CN}$ ;  $-\text{N-NH}_2$ ;  $-\text{N-NHR}^2$ ;  $-\text{N-NR}^2\text{R}^3$ ;  $-\text{N-OH}$ ; or  $-\text{N-OR}^2$ ;

each  $\text{R}^2$  is independently hydrogen; an optionally substituted or unsubstituted branched or unbranched lower alkyl, alkenyl or alkynyl;  $\text{CH}_3$ ;  $\text{CF}_3$ ; or vinyl bromide;

each  $\text{R}^3$  is independently hydrogen; optionally substituted or unsubstituted branched or unbranched alkyl, alkenyl or alkynyl;  $\text{CH}_3$ ;  $\text{CF}_3$ ; vinyl bromide;  $-\text{CR}^2\text{R}^2-\text{S}(\text{O})_n-\text{R}^2$ ;  $-\text{CR}^2\text{R}^2\text{NH}_2$ ;  $-\text{CR}^2\text{R}^2\text{NHR}^2$ ;  $-\text{CR}^2\text{R}^2\text{NR}^2\text{R}^2$ ;  $-\text{CR}^2\text{R}^2-\text{C}(=\text{O})\text{R}^2$ ; optionally substituted or unsubstituted aryl; optionally substituted or unsubstituted heterocycle; optionally substituted or unsubstituted alkylaryl; optionally substituted or unsubstituted alkylheterocycle; optionally substituted or unsubstituted aralkyl; or optionally substituted or unsubstituted heterocycle-alkyl;

each n is independently 0, 1 or 2;

each p is independently 0, 1, 2, 3, 4 or 5; and

wherein the optionally substituted branched or unbranched alkyl, alkenyl, alkynyl, lower alkyl, lower alkenyl; lower alkynyl; acyl; aryl; heterocycle; alkaryl; alkheterocycle; arylalkyl; or alkylheterocycle optionally is substituted with one or more of halogen;  $-\text{OH}$ ;  $-\text{OR}^2$ ;  $-\text{SH}$ ;  $-\text{SR}^2$ ; oxime; hydrazine;  $-\text{C}(=\text{O})\text{H}$ ;  $-\text{C}(=\text{W})\text{H}$ ;  $-\text{C}(=\text{O})\text{R}^2$ ;  $-\text{C}(=\text{W})\text{R}^2$ ;  $-\text{C}(=\text{O})\text{OH}$ ;  $-\text{C}(=\text{W})\text{OH}$ ;  $-\text{C}(=\text{O})\text{OR}^2$ ;  $-\text{C}(=\text{W})\text{OR}^2$ ;  $-\text{C}(=\text{O})\text{SH}$ ;  $-\text{C}(=\text{W})\text{SH}$ ;  $-\text{C}(=\text{O})\text{SR}^2$ ;  $-\text{C}(=\text{W})\text{SR}^2$ ;  $-\text{C}(=\text{O})\text{NH}_2$ ;  $-\text{C}(=\text{W})\text{NH}_2$ ;  $-\text{C}(=\text{O})-\text{NHR}^2$ ;  $-\text{C}(=\text{W})\text{NHR}^2$ ;  $-\text{C}(=\text{O})\text{NR}^2\text{R}^3$ ;  $-\text{C}(=\text{W})-\text{NR}^2\text{R}^3$ ;  $-\text{NH}_2$ ;  $-\text{NHR}^2$ ;  $-\text{NR}^2\text{R}^3$ ;  $-\text{NHSO}_2-\text{C}_{1-3}\text{alkyl}$ ;  $-\text{NR}^2\text{SO}_2-\text{C}_{1-3}\text{alkyl}$ ;  $-\text{NHCO}-\text{C}_{1-3}\text{alkyl}$ ;  $-\text{NR}^2\text{CO}-\text{C}_{1-3}\text{alkyl}$ ;  $-\text{S}(\text{O})_n-\text{R}^3$ ;  $\text{C}_{1-3}\text{alkoxy}$ ;  $\text{C}_{1-3}\text{thioether}$ ; or an amino acid residue;

in combination and/or alternation with one or more other anti-HIV agent, optionally in a pharmaceutically acceptable carrier or diluent.

Claim 29 (original): The method of any one of claims 19-28 wherein the host is a human.